Learning pointsPericardial disease in cancer is common and may be related to the cancer itself or cancer therapy.Constrictive pericarditis (CP) causes characteristic abnormalities in diastolic ventricular filling, but diagnosis should also attempt to determine the underlying aetiology. Diagnosis and subsequent management require multi-modality imaging alongside multidisciplinary involvement from cardiology, cardiothoracic surgery, histopathology, and microbiology, together with the physicians treating any potential causative underlying condition.Graft-vs.-host disease is a rare, but potentially reversible cause of CP, amenable to surgery and appropriate immunomodulation.

Introduction
============

Pericardial disease is common in patients with cancer---presenting either with pericarditis, pericardial effusions, pericardial masses, or pericardial constriction. It may be related to the underlying cancer diagnosis (such as with lymphoma or metastatic breast cancer-related effusions) or a complication of the administered cancer treatment. Constrictive pericarditis (CP) is characterized by pericardial fibrosis and thickening, leading to a loss in pericardial compliance, ultimately causing impaired ventricular filling.[@ytaa009-B1] Although now a relatively uncommon cause of heart failure; both diagnosis and management can be challenging, particularly in cancer patients. Detection of CP is reliant on appropriate imaging techniques.[@ytaa009-B2] Echocardiograms offer a functional assessment of cardiac physiology and can identify pericardial thickening, which can be characterized more elegantly using cross-sectional imaging modalities, such as magnetic resonance imaging or computed tomography. Furthermore, identifying the underlying aetiology is essential, as some causes of CP are reversible with timely medical management.[@ytaa009-B3] If established, surgical pericardectomy may represent the only viable option in delivering adequate functional recovery despite its high peri-operative risk.[@ytaa009-B4]

Timeline
========

  Time                                                                                                                                                  Events                                                                                                                                                                                                                                                                     
  ----------------------------------------------------------------------------------------------------------------------------------------------------- -------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------- --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  30 months prior                                                                                                                                       Diagnosis of acute myeloid leukaemia; treated with high-dose chemotherapy and subsequent allogeneic stem cell transplantation.                                                                                                                                             
  26 months prior                                                                                                                                       Episode of mild skin graft-vs.-host disease (GvHD); treated with oral prednisolone and ciclosporin with rapid resolution of symptoms.                                                                                                                                      
  Presentation                                                                                                                                          Slowly progressive exertional dyspnoea and peripheral oedema. Clinical features in keeping with pulmonary oedema.                                                                                                                                                          
  Transthoracic echocardiogram                                                                                                                          Normal biventricular size and systolic function with septal 'bounce'. Pericardial thickening and small pericardial effusion with evidence of constrictive physiology and moderate bi-atrial dilatation.                                                                    
  Impression                                                                                                                                            Constrictive pericarditis                                                                                                                                                                                                                                                  
  Treatment                                                                                                                                             Intravenous diuresis, high-dose oral steroids and diagnostic pericardiocentesis (350 mL blood-stained fluid drained---negative cytology and microbiology).                                                                                                                 
  1 month post                                                                                                                                          Cardiac magnetic resonance imaging (MRI)                                                                                                                                                                                                                                   Pericardial thickening suggestive of a constrictive/effusive pericarditis with evidence of ventricular interdependence on real-time free-breathing imaging. No myocardial late gadolinium enhancement.
  1--6 months post                                                                                                                                      Multiple prolonged admissions to hospital with diuretic-refractory pleural and peripheral oedema, New York Heart Association (NYHA) Class 3--4 requiring care home admission on discharge from hospital. Multidisciplinary team decision to proceed with pericardectomy.   
  6 months post (surgical treatment)                                                                                                                    Surgical partial pericardectomy---histology demonstrated presence of fibrous tissue in keeping with GvHD.                                                                                                                                                                  
                                                                                                                                                        Commenced on ruxolitinib 5 mg BD and continued high-dose oral diuretics.                                                                                                                                                                                                   
  18 months post (cardiology follow-up)                                                                                                                 Gradual improvement in functional status to NYHA Class 1--2, living independently and recently married.                                                                                                                                                                    
  Maintained on ruxolitinib on reducing diuretic doses with cardiac MRI showing only mild pericardial thickening with no ventricular interdependence.                                                                                                                                                                                                                                                                              

Case presentation
=================

A 74-year-old Caucasian man presented with significant exertional dyspnoea and peripheral oedema; progressive over a 12-month period. Of note, he had undergone allogeneic stem cell transplantation following high-dose chemotherapy (fludarabine/cyclophosphamide and methotrexate) 30 months previously for acute myeloid leukaemia. He had recovered well from this aside from an episode of skin GvHD which responded well to oral prednisolone and ciclosporin. He was known to have mild coronary artery disease (diagnosed by invasive coronary angiography), hypertension, and paroxysmal atrial fibrillation. His medication list was as follows Apixaban 5 mg twice daily, Atorvastatin 20 mg nocte, Omeprazole 20 mg daily, Ramipril 10 mg daily, Acyclovir 400 mg twice daily, Mycophenolate 500 mg twice daily, and Penicillin V 250 mg twice daily.

Clinical examination revealed a pulse of 110 b.p.m. (regular), blood pressure 98/60 mmHg, and JVP +8 cm. His oxygen saturations were 92% on room air with bilateral pleural effusions suggestive of pulmonary oedema and peripheral oedema to mid-thigh. Pericardial knock was heard, pulsus paradoxus, and Kussmaul's sign were absent. Baseline electrocardiogram demonstrated sinus tachycardia only. Chest radiography confirmed pulmonary oedema and pleural effusions. His c-reactive protein, N-terminal pro b-type natriuretic peptide, and troponin-T levels were elevated \[69 mg/L (reference range \< 5 mg/L), 2800 ng/L (reference range \< 400 ng/L), and 26 ng/dL (reference range \< 14 ng/dL), respectively\] but the remainder of his blood panel was unremarkable.

Transthoracic echocardiography (*[Figure 1A](#ytaa009-F1){ref-type="fig"}*) showed normal left ventricular dimensions with preserved systolic function (left ventricular ejection fraction 57%) with no hypertrophy or regional wall motion abnormalities. The right ventricular (RV) dimensions were within normal limits with normal function. Moderate bi-atrial dilatation and pericardial thickening were noted. The inferior vena cava measured 20 mm and collapsed \<50% with inspiration. The mitral inflow Doppler profile showed E:A ratio of 1.4:1. Respiratory variability was noted in both trans-mitral (\>30%) and trans-tricuspid (\>40%) filling pressures on Doppler echocardiography, with preserved septal tissue Doppler *E*' velocities suggestive of constrictive physiology[@ytaa009-B1] (*[Figure 1B *and* C](#ytaa009-F1){ref-type="fig"}*). Diagnostic pericardiocentesis drained 350 mL of blood-stained fluid, with negative cytology, immunohistochemistry, and microbiology. Computed tomography scanning of the patient's chest, abdomen, and pelvis revealed no evidence of recurrent malignancy or tuberculosis.

![Transthoracic echocardiography at presentation. (*A*) Subcostal two-dimensional view showing pericardial thickening and a small pericardial effusion (with preserved systolic function but septal 'bounce'). (*B*) Trans-tricuspid pulsed-wave Doppler imaging acquired during free breathing showing variation of 30% with inspiration suggestive of constrictive physiology. (*C*) Tissue Doppler imaging revealing preserved medial mitral annular *e*' velocities.](ytaa009f1){#ytaa009-F1}

Cardiovascular magnetic resonance (CMR) imaging confirmed a diagnosis of effusive CP, with significant pericardial thickening, bi-atrial enlargement, and ventricular interdependence (*[Figure 2A *and* B](#ytaa009-F2){ref-type="fig"}*) on real-time free breathing imaging. Tissue characterization found no evidence of myocardial oedema, focal fibrosis, or prior infarction.

![Cardiovascular magnetic resonance imaging. (*A* and *B*) Pre-operative cardiovascular magnetic resonance imaging---four-chamber (*A*) and mid-ventricular short-axis (*B*) views showing grossly thickened pericardium (arrowed) and bi-atrial dilatation. (*C* and *D*) Cardiovascular magnetic resonance acquired at 18-month post-surgery. Four-chamber (*C*) and short-axis (*D*) views highlighting reduction in pericardial thickening following pericardectomy and immunomodulation with ruxolitinib. Mild residual pericardial thickening can be noted remaining surrounding left ventricle lateral wall (arrowed; [Supplementary material online, *Videos S1--S5*](https://academic.oup.com/ehjcr/article-lookup/doi/10.1093/ehjcr/ytaa009#supplementary-data)).](ytaa009f2){#ytaa009-F2}

The aetiology of the CP was unclear, and management focused on intravenous diuretics alongside empirical high-dose steroids. Unfortunately, he remained New York Heart Association (NYHA) Class 3--4 with diuretic resistant heart failure, requiring multiple prolonged hospital admissions.

Partial pericardectomy (with removal of the anterior pericardium adherent to the RV free and anterior wall, constrained by a boundary of the phrenic nerves) and pericardial biopsy was undertaken following multidisciplinary discussion involving cardiology, cardiothoracic surgery, and haematology, for both diagnostic and therapeutic purposes. Given the pre-operative clinical state of the patient (NYHA Class 3--4) and the presence of very thick localized adhesions a partial, not radical, approach was undertaken, with the surgical team concerned about iatrogenic damage from attempting to remove these islands of adherent pericardium, with unacceptable risk should cardiopulmonary bypass be required. Following stripping of the thickened pericardium, the anterior cardiac surface was seen to move freely intra-operatively (*[Figure 3](#ytaa009-F3){ref-type="fig"}*). Histological analysis of stripped pericardial tissue displayed features of graft-vs.-host disease (GvHD). Consequently, ruxolitinib (JAK1/JAK2 tyrosine kinase inhibitor) was commenced as a GvHD salvage therapy alongside high-dose oral steroids.

![Intra-operative pericardectomy findings. Intra-operative image showing the thickened pericardium, especially noticeable surrounding the free wall of right ventricle (arrowed; [Supplementary material online, *Video S6*](https://academic.oup.com/ehjcr/article-lookup/doi/10.1093/ehjcr/ytaa009#supplementary-data)).](ytaa009f3){#ytaa009-F3}

Post-operatively the patient recovered and was discharged from hospital, with sustained clinical improvement over subsequent months. He had no further hospital admissions and his diuretic requirements reduced. At latest review, 12-month post-pericardectomy, his functional status was NYHA Class 1--2 and repeat cardiac imaging exhibited a reduction in pericardial thickness of the residual pericardium, with improved Doppler parameters and no evidence of ventricular inter-dependence by CMR imaging (*[Figure 2C *and* D](#ytaa009-F2){ref-type="fig"}*).

Discussion
==========

Constrictive pericarditis is now a relatively uncommon cause of heart failure, with diagnosis and management often problematic.[@ytaa009-B1] Diagnosis involves identification of characteristic imaging findings in conjunction with invasive haemodynamic assessment where required. Determining the underlying aetiology is more challenging, especially in the context of cancer, where the cause of pericardial disease is often multifactorial. Here, pericardial disease can either be linked directly to the cancer itself or cancer therapies (chemotherapy and radiotherapy); both can cause acute or chronic pericardial damage.[@ytaa009-B5]

Here, we describe a rare but potentially reversible cause of CP associated with GvHD. Graft-vs.-host disease contributes a major source of morbidity and mortality in patients following allogeneic haematopoietic stem cell transplantation,[@ytaa009-B6] with over half of allogeneic transplant recipients exhibiting clinical GvHD.[@ytaa009-B7] It is mediated via donor T-lymphocyte responses to host tissue; while the graft-vs.-tumour effect[@ytaa009-B8] confers beneficial effects against underlying malignancy, the immunological reaction to healthy host tissue can result in an inappropriate inflammatory response; manifesting as GvHD. Acute GvHD, occurring within the first 100 days post-haematopoietic stem cell transplantation, can be particularly severe,[@ytaa009-B9] affecting the skin, liver and gastrointestinal tract requiring swift aggressive immunosuppression.[@ytaa009-B8]^,^[@ytaa009-B10] Chronic GvHD has been closely compared to longstanding autoimmune connective tissue syndromes affecting multiple systems.[@ytaa009-B11] Cardiovascular presentations of GvHD are rare but have been described causing conduction pathway abnormalities, coronary artery disease,[@ytaa009-B12] and rarely pericarditis.[@ytaa009-B13]^,^[@ytaa009-B14]

Importantly, ascertaining the underlying aetiology enabled a targeted management strategy combining surgery with selective inhibition of the Janus-associated tyrosine kinases (JAK1 and JAK2) to be delivered via a multidisciplinary team involving the patient's haematologist, cardiologist, and cardiothoracic surgeon. Continued systemic immunomodulation with ruxolitinib resulted in further sustained improvements to both patient morbidity and performance. This suggests an important role for timely immunosuppression in CP associated with GvHD to dampen the chronic inflammatory processes that mediate irreversible pericardial thickening.

Conclusion
==========

This case describes a rare cause of CP, chronic GvHD that was successfully treated with a combined approach with surgical and targeted immunotherapy. This highlights the importance of multidisciplinary team involvement when managing patients with cardiovascular disease following cancer treatment, and the emerging need for cardio-oncology.
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